Market Cap 21.81B
Revenue (ttm) 3.18B
Net Income (ttm) 1.33B
EPS (ttm) N/A
PE Ratio 17.88
Forward PE 18.98
Profit Margin 41.94%
Debt to Equity Ratio 0.00
Volume 366,400
Avg Vol 515,564
Day's Range N/A - N/A
Shares Out 42.89M
Stochastic %K 51%
Beta 0.59
Analysts Strong Sell
Price Target $655.78

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 301 608 9292
Address:
1000 Spring Street, Silver Spring, United States
kcphaeton
kcphaeton Aug. 17 at 12:59 PM
$MNKD @amsteliam the board, and MIKE enriched themselves while the shareholders languished. A poorly executed commercialization of Afrezza. And still continue to do that. They got lucky with $UTHR I am sure this is why Rubric sees blood in the water because they as an activist will change the management team. 
2 · Reply
Outcomes
Outcomes Aug. 17 at 11:18 AM
$MNKD $UTHR .....“Due to the similarities in the mechanism of fibrosis between IPF and PPF, we are optimistic that anti-fibrotic therapies, such as inhaled treprostinil, will impact disease progression similarly in patients with these conditions." https://ir.unither.com/press-releases/2026/08-17-2026-120020653
0 · Reply
kcphaeton
kcphaeton Aug. 13 at 6:50 PM
$MNKD @Catalystinvestor nobody is bringing the share price down. It’s caused by institutional sellers running for the Door. Retail investors were thinking it’s a good deal for them, but they can’t move the needle. Martine we’ll probably get excited because $UTHR could offer $5 to $8 per share and people would instantly sell.
1 · Reply
clan
clan Aug. 13 at 1:07 PM
$MNKD Ultra rapid-acting = "The Need For Speed"! #technosphere #mannkind Mannkind's future is 🌞😎 $UTHR $SPY $AMGN
0 · Reply
AcceleratorModel
AcceleratorModel Aug. 12 at 5:22 PM
$UTHR flagging on the monthly , needs to get a move on
0 · Reply
Outcomes
Outcomes Aug. 11 at 8:12 PM
$UTHR ….screaming buy
0 · Reply
clan
clan Aug. 11 at 11:21 AM
$MNKD When there's somethin' strange in the neighborhood. Who ya' gonna call? Lasagna. $UTHR $BX $SCPH
1 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
clan
clan Aug. 9 at 12:46 PM
$MNKD Here's why hype and exuberance around Mannkind's progress will likely propel MNKD to over $50/sh by the end of 2028... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $1 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approved Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $8 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug -------- +$48/sh Take a 👀 🫵 $SPY and $QQQ 🤑
1 · Reply
Wolf1971
Wolf1971 Aug. 8 at 5:15 PM
$UTHR come on Martine when are you going to do female CEO workshop so your sisters gonna benefit from your secrets in breaking the glass ceiling
0 · Reply
Latest News on UTHR
United Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 9:00 AM EDT - 14 days ago

United Therapeutics Earnings Call Transcript: Q2 2026


United Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 9:00 AM EDT - 14 days ago

United Therapeutics Quarterly report: Q2 2026


United Therapeutics Slides: Q2 2026

Aug 5, 2026, 9:00 AM EDT - 14 days ago

United Therapeutics Slides: Q2 2026


United Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 9:00 AM EDT - 14 days ago

United Therapeutics Earnings release: Q2 2026


United Therapeutics reports Q2 EPS $7.27, consensus $6.86

2026-08-05T10:51:46.000Z - 14 days ago

United Therapeutics reports Q2 EPS $7.27, consensus $6.86


United Therapeutics acquires Thymmune Therapeutics

2026-07-02T10:35:12.000Z - 6 weeks ago

United Therapeutics acquires Thymmune Therapeutics


United Therapeutics Transcript: AGM 2026

Jun 26, 2026, 10:30 AM EDT - 7 weeks ago

United Therapeutics Transcript: AGM 2026


United Therapeutics says TETON-1 study published in NEJM

2026-05-18T20:21:29.000Z - 3 months ago

United Therapeutics says TETON-1 study published in NEJM


United Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 9:00 AM EDT - 3 months ago

United Therapeutics Earnings Call Transcript: Q1 2026


United Therapeutics Quarterly report: Q1 2026

May 6, 2026, 9:00 AM EDT - 3 months ago

United Therapeutics Quarterly report: Q1 2026


United Therapeutics Earnings release: Q1 2026

May 6, 2026, 9:00 AM EDT - 3 months ago

United Therapeutics Earnings release: Q1 2026


United Therapeutics Slides: Q1 2026

May 6, 2026, 9:00 AM EDT - 3 months ago

United Therapeutics Slides: Q1 2026


United Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

United Therapeutics Proxy statement: Proxy filing


United Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

United Therapeutics Proxy statement: Proxy filing


United Therapeutics Transcript: Study result

Mar 2, 2026, 8:30 AM EST - 6 months ago

United Therapeutics Transcript: Study result


United Therapeutics Press release: Study result

Mar 2, 2026, 8:30 AM EST - 6 months ago

United Therapeutics Press release: Study result


United Therapeutics Slides: Study result

Mar 2, 2026, 8:30 AM EST - 6 months ago

United Therapeutics Slides: Study result


United Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 9:00 AM EST - 6 months ago

United Therapeutics Earnings Call Transcript: Q4 2025


United Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 9:00 AM EST - 6 months ago

United Therapeutics Earnings release: Q4 2025


United Therapeutics Annual report: Q4 2025

Feb 25, 2026, 9:00 AM EST - 6 months ago

United Therapeutics Annual report: Q4 2025


United Therapeutics Slides: Q4 2025

Feb 25, 2026, 9:00 AM EST - 6 months ago

United Therapeutics Slides: Q4 2025


Flurry of Bullish Inflows Sends United Therapeutics Higher

Dec 3, 2025, 7:19 AM EST - 9 months ago

Flurry of Bullish Inflows Sends United Therapeutics Higher


United Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 10 months ago

United Therapeutics Earnings Call Transcript: Q3 2025


United Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 10 months ago

United Therapeutics Earnings release: Q3 2025


United Therapeutics Quarterly report: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 10 months ago

United Therapeutics Quarterly report: Q3 2025


United Therapeutics Slides: Q3 2025

Oct 29, 2025, 9:00 AM EDT - 10 months ago

United Therapeutics Slides: Q3 2025


United Therapeutics Transcript: Study Update

Sep 28, 2025, 12:30 PM EDT - 11 months ago

United Therapeutics Transcript: Study Update


United Therapeutics Press release: Study Update

Sep 28, 2025, 12:30 PM EDT - 11 months ago

United Therapeutics Press release: Study Update


United Therapeutics Slides: Study Update

Sep 28, 2025, 12:30 PM EDT - 11 months ago

United Therapeutics Slides: Study Update


United Therapeutics: Is UTHR Stock Still A Buy At $400?

Sep 3, 2025, 10:10 AM EDT - 1 year ago

United Therapeutics: Is UTHR Stock Still A Buy At $400?


United Therapeutics Earnings Call Transcript: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings Call Transcript: Q2 2025


United Therapeutics Quarterly report: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Quarterly report: Q2 2025


United Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Earnings release: Q2 2025


United Therapeutics Slides: Q2 2025

Jul 30, 2025, 9:00 AM EDT - 1 year ago

United Therapeutics Slides: Q2 2025


kcphaeton
kcphaeton Aug. 17 at 12:59 PM
$MNKD @amsteliam the board, and MIKE enriched themselves while the shareholders languished. A poorly executed commercialization of Afrezza. And still continue to do that. They got lucky with $UTHR I am sure this is why Rubric sees blood in the water because they as an activist will change the management team. 
2 · Reply
Outcomes
Outcomes Aug. 17 at 11:18 AM
$MNKD $UTHR .....“Due to the similarities in the mechanism of fibrosis between IPF and PPF, we are optimistic that anti-fibrotic therapies, such as inhaled treprostinil, will impact disease progression similarly in patients with these conditions." https://ir.unither.com/press-releases/2026/08-17-2026-120020653
0 · Reply
kcphaeton
kcphaeton Aug. 13 at 6:50 PM
$MNKD @Catalystinvestor nobody is bringing the share price down. It’s caused by institutional sellers running for the Door. Retail investors were thinking it’s a good deal for them, but they can’t move the needle. Martine we’ll probably get excited because $UTHR could offer $5 to $8 per share and people would instantly sell.
1 · Reply
clan
clan Aug. 13 at 1:07 PM
$MNKD Ultra rapid-acting = "The Need For Speed"! #technosphere #mannkind Mannkind's future is 🌞😎 $UTHR $SPY $AMGN
0 · Reply
AcceleratorModel
AcceleratorModel Aug. 12 at 5:22 PM
$UTHR flagging on the monthly , needs to get a move on
0 · Reply
Outcomes
Outcomes Aug. 11 at 8:12 PM
$UTHR ….screaming buy
0 · Reply
clan
clan Aug. 11 at 11:21 AM
$MNKD When there's somethin' strange in the neighborhood. Who ya' gonna call? Lasagna. $UTHR $BX $SCPH
1 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
clan
clan Aug. 9 at 12:46 PM
$MNKD Here's why hype and exuberance around Mannkind's progress will likely propel MNKD to over $50/sh by the end of 2028... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $1 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approved Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $8 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug -------- +$48/sh Take a 👀 🫵 $SPY and $QQQ 🤑
1 · Reply
Wolf1971
Wolf1971 Aug. 8 at 5:15 PM
$UTHR come on Martine when are you going to do female CEO workshop so your sisters gonna benefit from your secrets in breaking the glass ceiling
0 · Reply
Wolf1971
Wolf1971 Aug. 8 at 2:14 PM
$UTHR this CEO was recognized as top female CEO! Kudos! Shattering the glass ceiling am I right
0 · Reply
OptionRunners
OptionRunners Aug. 7 at 7:38 PM
$UTHR running into the close. These are trading $5.50-$6 now from $1.90.
0 · Reply
Michaelluh
Michaelluh Aug. 7 at 4:03 PM
$MNKD $UTHR I’m surprised more people aren’t talking about what UTHR has laid out. This isn’t a one-year growth story. United has mapped a multi-indication expansion strategy across Tyvaso DPI and ralinepag DPI extending from roughly 2027/28 into the early 2030s. PAH → PH-ILD → IPF → PPF. Every successful indication potentially expands the addressable market feeding MNKD’s DPI royalty engine. And that’s only ONE part of the story. Add FUROSCIX/ReadyFlow, Afrezza adult + pediatric growth and MNKD-201, and we now have enough visibility to begin modeling MannKind’s revenue trajectory roughly seven years out. Wall Street is still looking quarter to quarter. I’m looking at 2033.
2 · Reply
peloswing
peloswing Aug. 6 at 9:42 PM
$UTHR Unusual Flow 🐳 $4M of the $550 calls for 8/21 🟢
0 · Reply
whiskyqueen
whiskyqueen Aug. 6 at 5:54 PM
$VKTX So we’ve spent the last year or so pounding the table on the possibility of best in class, looking at every angle of this investment. The one and only thing that keeps me up at night that really isn’t discussed on this board, is the possibility of Viking showing superiority over Zep, Reta or even both. What do you think happens when Lilly’s moat is challenged by a little guy? Wouldn’t they unleash legal hell on the patents for Zep to at a bare minimum tie Viking up in court and push their timeline to market back by at the very least a year, even if they know they will lose? Seen it several times over the years, $UTHR and $LQDA come to mind. Is the 2735 patent really bomb proof?
4 · Reply
OptionRunners
OptionRunners Aug. 6 at 2:59 PM
Quick $10 pop in $UTHR ... spiky with these flows
0 · Reply
OptionRunners
OptionRunners Aug. 6 at 2:56 PM
Another 5,000 in $UTHR. 10,000 total now. But have to see if they all carry over to the OI tomorrow. Stock popping to highs with it
0 · Reply
OptionRunners
OptionRunners Aug. 6 at 2:37 PM
$UTHR $950K into these August bull seagulls. They reported earnings yesterday
1 · Reply
Wolf1971
Wolf1971 Aug. 6 at 2:06 PM
$UTHR didn’t Martine get an award and a magazine cover for being a top lady CEO? Wall Street isn’t misogynistic, at all.
0 · Reply
cuttail07
cuttail07 Aug. 6 at 10:23 AM
$UTHR Stranglehold on PAH clearly eroding. No longer reaffirming or revising (I.e.they are removing) full year guidance. Their confidence in achieving a 4billion dollar revenue run rate with legacy products by end of 2027 is also clearly dampened. I expect dwindling or stagnant revenues this year with the next share price catalyst dependent on TAM expansion through FDA approval of Tyvaso nebulizer in IPF. No rush to enter or add you a position right now. I may consider doing so ahead of the PDUFA date, once known. Once selling into the IPF market, revenue and EPS should re-accelerate.
0 · Reply
Gambaa
Gambaa Aug. 6 at 12:06 AM
$UTHR Some of the most resilient suckers out there ill give you that. Revenue disappearing, ceo dumping, pipeline pathetic.
0 · Reply
clan
clan Aug. 5 at 6:55 PM
$MNKD $UTHR Mannkind is like Royalty -- 10% of a couple BILLION dollars a year is ... is ... is ....... a LOT of dollars!
1 · Reply